MicroVascular Tissues Announces Peer-Reviewed Publication of Positive HIFLO Clinical Trial Results Using mVASC® Graft

Data on Nonhealing Wagner 1 & 2 Neuropathic Diabetic Foot Ulcers Published in IWJ. Additional Data to be Presented at Upcoming 2021 SAWC and DFCon Meetings.
SAN DIEGO, CA, UNITED STATES, October 20, 2021 /EINPresswire.com/ — MicroVascular Tissues, Inc., (MVT), a regenerative tissue company, today announced that the results of its HIFLO Trial assessing patient outcomes after treatment with mVASC® Microvascular Tissue Graft product have been published in an article entitled, “Improved Healing of Chronic Diabetic Foot Wounds in a Prospective Randomized Controlled Multicenter Clinical Trial with a Microvascular Tissue Allograft” in the International Wound Journal (IWJ), one of the preeminent journals aimed at improving patient care in the wound care industry.

The HIFLO trial was a Level 1, prospective, single-blind, randomized clinical trial conducted at six U.S. sites that assessed outcomes in 100 subjects with nonhealing Wagner grade 1 and 2 neuropathic diabetic foot ulcers (DFUs). The primary endpoint was the percentage of ulcers healed within 12 weeks. Secondary and research endpoints included wound area percent reduction, time to healing, improvement in blood flow (perfusion) and peripheral neuropathy … read more

Newsletter Signup

Subscribe to our weekly newsletter below for an update of everything from the week